

Sharp Oncology Service Line

Incorporating Updated Guidelines into the Management of Breast Cancer: Case Studies and Best Practices

A **knowledge** activity for Sharp-affiliated or community physicians, pharmacists, nurses, and allied health professionals.



Thursday, June 13, 2019

5:30 p.m. – Welcome reception and dinner

6 p.m. to 8 p.m. – Presentation and panel

Sharp HealthCare Corporate Building Auditorium

8695 Spectrum Center Blvd., San Diego, CA 92123

Christy A. Russell, MD - *Oncologist, Senior Director US Medical Affairs*
Genomic Health, Inc., Redwood City, California

Dr. Russell is a member of the American College of Physicians, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the American Society of Breast Surgeons. Dr Russell served on the American Cancer Society Cancer Action Network National Board of Directors, and served as the Chairman of the Board. She was a member of the American Cancer Society, Inc. National Board of Directors and chaired the National Reach to Recovery advisory group. She served as a Director on the board of the California Division of the American Cancer Society and was President of the board. She currently is an Honorary Life Member of the California Division of the American Cancer Society. She served as the Chief of staff at USC/Norris Cancer center. She was the Director of the USC/Norris Breast Cancer Center, the director of utilization review at USC/Norris Cancer Center and Co-Chair of the USC Comprehensive Cancer Center Data Safety Monitoring Board.

Educational Objectives: Following this presentation, participants should be able to:

1. Articulate the importance of clinical staging and the resources used for comprehensive staging
2. Summarize the importance of timely clinical staging, pathological staging, and prognostic staging and its effect on treatment decisions
3. Describe the significance of biomarkers in breast cancer diagnoses and their utility in treatment decisions
4. List the benefits of reflex testing in breast cancer.
5. Describe the factors used in breast cancer risk stratification

Educational Objectives: Following this panel, participants should be able to:

1. Describe the role age plays in ensuring a comprehensive breast cancer work-up prior to treatment initiation
2. Identify the role hereditary cancer mutations play in breast cancer treatment decisions
3. List the staging considerations for patients undergoing neo-adjuvant treatment
4. Identify how pregnancy effects biomarker testing and treatment decisions
5. Describe the approach to clinical staging for unexpected breast cancer malignancies

Complimentary registration.

To register, please visit <https://sharp.cloud-cme.com/oncologycaseandpractices>

Commercial Support: None



Accreditation: Sharp HealthCare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. **CME Credit:** Sharp HealthCare designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Accreditation: Sharp HealthCare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. **CPE Credit:** Sharp HealthCare designates this live activity for a maximum of 2 contact hours (.2 CEUs). Partial credit will not be awarded. Pharmacists can verify their credits at <http://www.cpemonitor.net> within 30 days of completion of activity. UAN: 0571-0000-19-034-L01-P